IL33 and acute kidney injury: In line with these observations, Stremska and co-workers designed IL-233, a novel IL-2 and IL-33 hybrid cytokine, whose administration efficiently expanded ST2 expressing Tregs and ILCs in CDDP-injured kidneys and completely attenuated AKI and inflammation [128].